Sign in / Register 
Goat F(ab')2 IgG-SPRD
Cat. No.:
0110-13
Goat F(ab')2 IgG-PE/CY5 (SPRD) for use as a control in flow cytometry assays.
$132.00
| Isotype | Goat F(ab')2 IgG |
|---|---|
| Source | Pepsin digest of Goat IgG (SB Cat. No. 0109) |
| Conjugate | SPRD (R-phycoerythrin/Cyanine 5) |
| Buffer Formulation | Phosphate buffered saline containing < 0.1% sodium azide and a stabilizer |
| Clonality | Polyclonal |
| Concentration | Lot specific |
| Volume | 1.0 mL |
| Recommended Storage | 2-8°C; Avoid exposure to light; Do not freeze |
| Trademark Information | Spectral Red® is a registered trademark of Southern Biotechnology Associates, Inc. Spectral Red® is a PE/CY5 tandem conjugate Cy® is a registered trademark of Global Life Sciences Solutions Germany GmbH |
| Applications | Quality tested applications for relevant formats include - Flow Cytometry 1-3 ELISA FLISA Other referenced applications for relevant formats include - Immunocytochemistry 4 |
| RRID Number | AB_2793961 |
Documentation
Certificate of Analysis Lookup
Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view
- 1. Coccia MA, Brams P. High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. J Immunol. 1998;161:5772-80. (FC)
- 2. Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther. 2008;10:R22. (FC)
- 3. Delaleu N, Madureira AC, Immervoll H, Jonsson R. Inhibition of experimental Sjögren's syndrome through immunization with HSP60 and its peptide amino acids 437-460. Arthritis Rheum. 2008;58:2318-28. (FC)
- 4. Montalvão F, Almeida GM, Silva EM, Borges VM, Vasconcellos R, Takiya CM, et al. Apoptotic lymphocytes treated with IgG from Trypanosoma cruzi infection increase TNF-α secretion and reduce parasite replication in macrophages. Eur J Immunol. 2010;40:417-25. (ICC)
See All References
